oncology 5 Flashcards

1
Q

blood tests for cancer that have some use in dogs?

A
  • cell-free DNA
  • nucleosomes
    > small fragments of DNA wrapped around a histone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is a cell free DNA test? what can it detect? what types of cancer is it useful for and what information does it give us?

A
  • apoptosis and necrosis of tumour cells releases cfDNA into blood
  • detect mutations from 30 types of cancer
  • most mutations cannot be confidently linked to a specific cancer yet
  • only report the suspected cancer type for some instances of canine lymphoma, for which the assocaited mutations are well-defined
    > otherwise, the results will only indicate whether cancer-related mutations were found or not found - “cancer signal detected”
    ()
    results in trial:
  • Sn 54.7%
  • Sp 98.5%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are nucleosomes and what is their use in cancer detection? limitations?

A
  • small fragments of DNA wrapped around a histone octamer core
  • nucleosome quantiffication can identify patients who may have a cancer
    > must then be confirmed by follow up procedures
    > will not differentiate between systemic inflammatory illness and cancer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

nucelosome blood test is best at detecting what type of cancers? Sn and Sp?

A
  • best detects systemic cancers with a high cellular turnover rate
    > identified 82% of hemangiosarcoma & 77% of lymphomas
    > detected 49.8% of all cancers in dogs with specificity of 97%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

how to biopsy a urothelial carcinoma and why?

A
  • ultrasound-guided traumatic catheterization biopsy, biopsy via cystoscopy, or surgical
    biopsy (change gloves & equipment)
  • spreads easily by seeding, therefor not aspirated through unaffected areas
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

molecular (gene) testing is useful for what type of cancer (at least in people)? what type of test for dogs? how good is it?

A

urothelial carcinoma
> looks for gene mutations
* CADET® BRAF for Diagnosis & Monitoring of
Canine TCC/UC
* evaluates urine for cells with the BRAF mutation or specific copy number variations
(CNV) associated with TCC/UC
* identify 95% of TCC/UC cases
* extremelylowlimitofdetectionof10
mutation‐bearing cells allows early diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what is fidocure?

A

Precision Medicine
* DNA sequencing of tumour >. allow targetted therapies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is vidium animal health and its use?

A
  • SearchLight DNA
  • next generation diagnostic test that identifies mutations in 120 cancer genes
  • “identifies drug therapies that target those
    specific mutations as well as therapies that are unlikely to be effective or may even result in accelerated tumor growth”
    ()
  • in human oncology, “precision therapies” exist that are directed against a cancer’s specific mutations
  • fewer precision therapies exist in veterinary medicine > will become increasingly available as we increase our understanding
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

hemangiosarcoma clinical signs depend on

A
  • anatomic site
    – +/‐ metastases
    – tumour size
    – tumour rupture
  • coagulopathies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

hemangiosarcoma clinical signs / presenting complaints, depending on their underlying cause:

A
  • Anatomic site
    > muffled heart sounds
    > weak femoral pulses
  • tumour size
    > abdominal distension
    > noticeable subcutaneous mass
  • coagulopathies
    > bruising
    > pale mucous membranes
  • tumour rupture
    > collapse
    > lethargy (sometimes repeated episodes)
    > pale mucous membranes
    > abdominal distension
  • cardiac arrhythmias
    > lethargy
    > collapse
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how often are splenic masses neoplastic? how many of these are HSA vs other possibilites? what increases this likelihood?

A
  • 2/3 are neoplastic
    > 2/3 of these are hemangiosarcoma
    > increased likelihood of HSA if hemoabdomen
  • other neoplasms:
    > lymphoma
    > MCT
    > malignant histocytosis
    > soft tissue sarcoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

non-neoplastic splenic mass possibilities

A
  • hematoma
  • hemangiosarcoma
  • extra-medullary hematopoiesis (EMH)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

options for splenic mass diagnosis, and how good they are:

A

– Abdominal ultrasound (US)
> visualize mass - cavitated vs. solid, solitary vs. multiple?
> abdominal effusion?

– Fine needle aspirate (FNA) + cytology of mass
> low yield for HSA
> may not be low yield for other splenic tumour types

– Diagnostic abdominocentesis + cytology
> low yield for diagnosis
> characterize effusion
» Does the peripheral PCV = effusion PCV?

  • Excisional biopsy
    > splenectomy
    > often only way to diagnose HSA
  • Immunohistochemistry (IHC)
    > may be needed for diagnosis
    > Von Willebrand factor antigen, CD31
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

3 common primary sites for hemangiosarcoma

A
  • spleen (28-50%)
  • right atrium and auricle (3-50%)
  • skin or subcutaneous (13%)

Other sites:
- liver, kidney, bladder, prostate, lung, etc.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

cardiac mass differential diagnoses

A

– Neoplasia
* Hemangiosarcoma*
* Chemodectoma (heart base mass)
* Ectopic thyroid carcinoma
* Lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

diagnostic methods for cardiac mass? effectiveness of methods and usual method?

A
  • Cardiacultrasound
    > visualize mass – may be difficult, especially if no effusion
    > pericardial effusion
    > location of the mass
  • FNA + cytology of mass
    > almost never performed
  • Diagnostic/therapeutic pericardiocentesis + cytology
    > low yield for diagnosis
  • excisional biopsy
    > auriculectomy > not common
  • Diagnosis is often presumptive for cardiac HSA
17
Q

subcutaneous mass differential diagnoses:

A
  • Neoplasia
    > hemangiosarcoma
    > mast cell tumour
    > soft tissue sarcoma
    > histiocytic sarcoma
  • non-neoplastic or benign
    > cyst
    > lipoma
18
Q

subcutaneous mass diagnostic methods? which are not as useful?

A
  • Focal ultrasound of subcutaneous tissue
    > may not visualize mass
  • FNA + cytology
    > low yield
  • Cytology of fluid pocket (if present)
    > low yield > often just hemorrhage
  • excisional biopsy
19
Q

what does staging tell us? what do stages 1, 2, 3 mean?

A
  • Stage 1: tumour confined to the primary site
  • Stage 2: tumour with regional lymph node metastasis or rupture
  • Stage 3: any tumour with distant metastasis or multicentric disease
20
Q

methods for HSA staging

A
  • CBC
  • Abdominal Ultrasound
  • Biochemical Profile
  • Thoracic radiographs
  • Echocardiogram
  • Coagulogram
21
Q

CBC results that we may see with HSA

A
  • anemia
    > microangiopathic hemolytic anemia (MAHA)
    » schistocytes
    » acanthocytes
  • thrombocytopenia
22
Q

what may we see on abdominal US in HSA case? probablilities?

A

– Spleen, liver, or omentum nodules
– even for cardiac HSA
~30% will have mets to spleen
~40% will have mets to other organs

23
Q

what proportion of splenic HSA will met to heat? how can we see this?

A

<10%of splenic HSA will met to heart
- can see with cardiac ultrasound

24
Q

how common is metastasis for splenic, cardiac, and subcutaneous HSA?

A
  • Splenic HSA – up to 70% will have metastasis at diagnosis
  • Cardiac HSA – 15‐70% will have metastasis at diagnosis
  • Subcutaneous HSA‐ ~18% will have metastasis at diagnosis
25
Q

HSA Prognostic factors
- survival rates?

A
  • Clinical stage is negative prognostic factor
  • Survival varies with location & stage
  • Short survival times (20‐60 days)
    > except dermal or conjunctival / 3rd eyelid HSA
26
Q

HSA Prognosis? with surgery alone? +chemo? if metastasis?

A
  • Poor
  • survival varies with location & stage
  • short survival times (20‐60 days)
    > except dermal or conjunctival / 3rd eyelid HSA
    ()
  • surgery alone
    > 60 day median survival time (10% 1 year survival)
  • surgery + chemo
    > median survival ~6 months
  • death typically due to metastasis to other primary organs
27
Q

splenic HSA treatment options? results?

A

Surgery only
- splenectomy (radical surgical excision)
> local therapy
- median survival time = 2-3 months
- 1 year survival 10%

Surgery + chemo
– MST = 4.5‐8 months
– 1 year survival 30%

Surgery + I’m Yunity immunotherapy
- local and systemic therapy
> MST ~6 months

28
Q

chemo drugs used for splenic HSA

A
  • Doxorubicin (Adriamycin®)
    – VAC
    > vincristine, adriamycin, cyclophosphamide
29
Q

Cardiac HSA treatment

A

Surgery
- pericardectomy
> prevents immediate danger of cardiac temponade
- auriculectomy or mass removal
> uncommon
> +chemo; MST = 6 months

Chemotherapy alone
- MST ~4 months

30
Q

Subcutaneous HSA treatment

A

Surgery + chemotherapy
– MST – 6 months
– 1 report suggests longer survival

Chemotherapy only
– MST – 83 days